Premium
BCNU (1,3), BIS(B‐chloroethyl)‐1‐nitrosourea. Effects on advanced Hodgkin's disease and other neoplasia
Author(s) -
Lessner Howard E.
Publication year - 1968
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196808)22:2<451::aid-cncr2820220224>3.0.co;2-z
Subject(s) - medicine , nitrosourea , disease , limiting , bone marrow , chemotherapy , oncology , gastroenterology , mechanical engineering , engineering
Thirty‐one patients with advanced Hodgkin's disease generally resistant to the standard chemotherapeutic agents were treated with BCNU. Unequivocal, dramatic and rapid responses were obtained in 17. The median duration of maintained remissions was over 120 days with eight patients still in remission at the time of writing. Responses were also noted in patients with lymphosarcoma and reticulum cell sarcoma, though to a lesser degree than with Hodgkin's disease. Bone marrow depression was the limiting toxic manifestation, characteristically delayed in onset and lasting 2 to 3 weeks. These results indicate a definite role for BCNU in the continuing management of patients with Hodgkin's disease.